Phase 2 N=25 Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence
Esophageal Squamous Cell Carcinoma
Primary: 1-year Relapse-free Survival Rate — 14.3 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=911 Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)
Peanut Allergy
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) — 866; 42 Participants
N/A N=90 Pivotal Study Of A Dual Epicardial & Endocardial Procedure (DEEP) Approach
Atrial Fibrillation · Persistent or Longstanding Persistent Atrial Fibrillation
Primary: Primary Effectiveness Endpoint — 61 Participants
Phase 3 N=403 Homeless Care Management App
Substance Use Disorders · Mental Health Impairment · Health Behavior
Primary: Number of Case Management Sessions Completed — 9.39; 7.69; 8.46 number of sessions
Phase 1 N=41 Anthrax AV7909 Liquid vs Lyophilized
Anthrax · Anthrax Immunisation
Primary: Number of Participants With Serious Adverse Events (SAEs). — 0; 0 Participants
Phase 2 N=547 B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis
Atopic Dermatitis · Pruritus
Primary: Mean Change in Worst Itch Numeric Rating Scale (WI-NRS) — -2.8; -2.8; -2.1 score on a scale — p=0.0148
Phase 2 N=36 A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS
Acute Myeloid Leukemia · Myelodysplastic Syndromes
Primary: Part A: Maximum Tolerated Dose (MTD) of Bemcentinib (BGB324) — 600; 200 mg
N/A N=205 Sculptra for Correction of Midface Volume Deficit and/or Midface Contour Deficiency
Midface Volume Deficit
Primary: Percentage of Participants With 1 Point Improvement From Baseline on the Medicis Midface Volume Scale (MMVS) as Measured by the Blinded Evaluator at Month 12 — 68.8…
Phase 2 N=48 CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
Colorectal Cancer · Colon Cancer · Rectal Cancer
Primary: PHASE I: Recommended Dose for Phase II Study — 1,000 mg/m^2
N/A N=44 Assessment of CSF Shunt Flow With Thermal Measurements A
Hydrocephalus
Primary: Study Device Sensitivity — 88 percent
N/A N=38 tDCS and Cognitive Efficiency in Ageing
Aging · Mild Cognitive Impairment · Alzheimer Disease
Primary: Complutense Verbal Learning Test (TAVEC) - Memory — 0.94; -0.81; 1.65; -0.31 units on a scale
Phase 1 N=22 A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease
Gastroesophageal Reflux Disease
Primary: Maximum Drug Concentration at Steady-state (Cmax,ss) of Vonoprazan — 16.2; 42.1 ng/mL
N/A N=40 Multi-component Workplace Energy Balance Intervention
Abdominal Obesity
Primary: Change in Visceral Adipose Tissue (VAT), Measured in kg — .04; -0.10 kg
Phase 2 N=142 Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
Primary: Percent Change in Hepatic Fat Fraction by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) From Baseline — -11.31; -27.59; 2.52; -28.68 percent change…
Phase 2 N=12 A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Participants With Chronic Hepatitis B
Hepatitis B
Primary: Percentage of Participants Achieving Serum Hepatitis B Virus Surface Antigen (HBsAg) Level Less Than (<) Lower Limit of Quantitation (LLOQ) — 25 Percentage of participants